Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists

Gitau, Kevin; Howe, Holly S.; Ginsberg, Lydia; Perl, Jeffrey; Ailon, Jonathan

doi:10.1016/j.xkme.2022.100453

Cited by 4 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24 While we might expect a higher use of cannabis for medical purposes in KT candidates, a Canadian nationwide survey reported that only 10% of nephrologists prescribed cannabis mainly due to a lack of familiarity with pharmacokinetics and formulations. 25 Patients with reported cannabis use in our study cohort were more likely to be younger, male sex and of Caucasian ethnicity, in line with previous studies. 4,[39][40][41][42][43] Nevertheless, heterogeneity across ethnicity has been reported.…”

Section: Discussionsupporting

confidence: 91%

“…Furthermore, patients could have underreported their cannabis use wishing to be approved for transplant because cannabis was an illegal drug before October 2018 in Canada 24 . While we might expect a higher use of cannabis for medical purposes in KT candidates, a Canadian nationwide survey reported that only 10% of nephrologists prescribed cannabis mainly due to a lack of familiarity with pharmacokinetics and formulations 25 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant

Rodríguez‐Ramírez,

Tang,

et al. 2024

Clinical Transplantation

View full text Add to dashboard Cite

BackgroundThe association between cannabis use and access to waitlisting, transplantation, and post‐transplant outcomes remains uncertain.MethodsPatients referred for kidney transplant (KT) to the University Health Network from January 1, 2003, to June 30, 2020, and followed until December 31, 2020, were included. Predictors of reported cannabis use were examined using a logistic regression model. The association between cannabis use and time to clearance for KT, undergoing KT, and post‐transplant outcomes was evaluated using Cox proportional hazards models.ResultsAmong 3734 patients, the prevalence of reported cannabis use was 11.8%. Cannabis use was associated with a lower likelihood of KT clearance (adjusted hazard ratio [aHR] .82 [95% confidence interval (CI): .72, .94]). Once cleared for KT, cannabis use did not predict the subsequent receipt of KT (aHR .92, [95% CI: .79, 1.08]). Among 2091 KT recipients, cannabis use was associated with a higher likelihood of biopsy‐proven acute rejection (aHR 1.55, [95% CI: 1.06, 2.27]). The relative hazard of death‐censored graft failure was similarly elevated (aHR 1.60 [95% CI: .95, 2.72]). Cannabis use did not predict total graft failure (aHR 1.33 [95% CI: .90, 1.96]), death with graft function (aHR 1.06 [95% CI: .59, 1.89]), or hospital readmission in the first‐year post‐transplant (aHR 1.26 [95% CI: .95, 1.68]).ConclusionsCannabis users have less access to transplantation and an increased risk of acute rejection, possibly leading to more graft loss. Further studies are warranted to understand possible mechanisms for the increased risk of allograft immune injury among cannabis users.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant

Rodríguez‐Ramírez,

Tang,

et al. 2024

Clinical Transplantation

View full text Add to dashboard Cite

show abstract

“…First, Physicians approving MC appear to hold a dual perspective of MC, perceiving it as a harmful and illegal drug, but also as a potential medicine (Zolotov et al, 2018). Physicians tend to advocate MC treatment based on their own experiences of treating patients with MC in their practice (Rønne et al, 2021; Zolotov et al, 2019), yet they tend to report insufficient knowledge concerning MC and its effects (Gitau et al, 2022; Zarhin et al, 2020). A recent qualitative study focusing on Australian physicians reported that MC prescribing was accompanied by ambiguities around its effectiveness, the political process involved in its rollout and the prescribing process (Hallinan et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Negative experiences of patients using medicinal cannabis: A systematic review of qualitative studies

Gliksberg

Kushnir

Sznitman

et al. 2023

Journal of Clinical Nursing

View full text Add to dashboard Cite

Aims and ObjectivesIn this study, we systematically reviewed qualitative studies concerning patients' experience with medicinal cannabis (MC) use, to gain insight into the negative effects of MC.BackgroundOver the past decades, the use of MC for therapeutic purposes has increased. However, there is conflicting and insufficient data on possible negative physiological and psychological effects of MC treatment.DesignA systematic review was conducted and the PRISMA guidelines were adopted. Literature searches were conducted using PubMed, PsycINFO and EMBASE. Critical Appraisal Skills Programme (CASP) qualitative checklist used to assess risk of bias in the included studies.MethodsWe included studies focusing on conventional medical treatment using cannabis‐based products, approved by a physician for a particular health issue.ResultsOf the 1230 articles identified in the initial search, eight articles were included in the review. Following the compilation of themes in the eligible studies, six themes were identified: (1) MC approval; (2) administrative barriers; (3) social perception; (4) MC misuse/widespread effect; (5) adverse effects; and (6) dependence or addiction. These were grouped into two meta‐themes: (1) administrative and social aspects of MC use; and (2) experiences of the effects of medicinal cannabis.ConclusionsOur findings call for specific attention to unique consequences associated with MC use. Further research is needed in order to assess the degree to which negative experiences associated with MC use may affect various aspects of patients' medical condition.Relevance to clinical practiceDescribing the complex experience of MC treatment and its spectrum of consequences for patients may enable physicians, therapists and researchers to provide more attentive and accurate MC treatment to their patients.Patient or public contributionIn this review, patients' narratives were explored, yet the research methods did not directly involve patients or the public.

show abstract

“…The multicenter study was carried out in the Czech Republic, Denmark, Germany, Ireland, the Netherlands, Portugal, Spain & and the United Kingdom. Four studies originated from Canada [30], [35], [38], [40], [41], whereas two studies originated from the United Kingdom [33], [34].…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Further, different RCT classes composing the group include a double-blinded randomized controlled trial, phase II double-blinded trial, phase II randomized, wait-list controlled clinical trial. Additional 5 retrospective studies [29], [35]- [38], [40], and one open-label pilot study were included in the review [29].…”

Section: Study Characteristicsmentioning

confidence: 99%

Psychopharmacology: Examine the Emerging Pharmaceutical Treatments for Mental Health Conditions and their Effectiveness Compared to Traditional Medication

Alnaher

2023

JSPRS

View full text Add to dashboard Cite

Study background: Mental health poses health, economic, and social burdens worldwide. The existing pharmaceutical interventions against mental diseases produce undesirable adverse effects, creating the need for the exploration of new treatments for more effective medications that do not yield adverse effects. Methods: The present review involved a literature search from electronic databases, including PubMed, ProQuest, Google Scholar, eb of science, and PsycINFO, and was conducted based on the Patient, Intervention, Comparison, Outcomes, and Studies (PICOS), protocol, and the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) checklist. Two independent reviewers were assigned study selection and data collection processes that included 16 studies in the review. Results: A review comparing the effectiveness of emerging pharmaceutical interventions against mental illnesses found that the psychedelic class of medications and cannabinoids are emerging effective medications against mental illnesses, including Major Depressive Disorders (MDD), patients with Treatment-Resistant Depression (TRD), and Post-Traumatic Stress Disorder (PSTD). However, the medications produce mild adverse effects. Keywords - Emerging mental health treatments, Effective medications, traditional medicines, mental health, Psychomarmacology treatment, Psychopharmacology efficacy.

show abstract

Therapeutic Cannabis Use in Kidney Disease: A Survey of Canadian Nephrologists

Cited by 4 publications

References 28 publications

Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant

Cannabis use is associated with reduced access to kidney transplantation and an increased risk of acute rejection post‐transplant

Negative experiences of patients using medicinal cannabis: A systematic review of qualitative studies

Psychopharmacology: Examine the Emerging Pharmaceutical Treatments for Mental Health Conditions and their Effectiveness Compared to Traditional Medication

Contact Info

Product

Resources

About